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Summary The growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients
with ovarian malignancy, benign ovarian tumours and non-tumour related gynaecological conditions have
been investigated using an ovarian carcinoma cell line (OAW 42), mesothelial cells (58MC) and rat kidney cells
(NRK-49F). Colony stimulating activity (CSA) for tumour cells and transforming activity (TA) for
mesothelial cells were weakly correlated, but whereas elevated TA was tumour-associated, CSA was not.
However, TA was not cancer-associated and, although the difference between the mean TA values of benign
and malignant cyst fluids was of borderline significance, some benign cyst fluids from cystadenomas showed
high TA values. Higher levels of TA in the cystadenomas showed a significant correlation with the menopausal
status of the patient and higher levels of TA in the malignant cyst fluid/peritoneal fluid groups were associated
with more advanced disease. Results indicated that some fluids contained TGF-p-like activity, but there was
no direct evidence for th-e presence of TGF-a/EGF-like activity in the fluids. Heparin inhibited clonogenic
growth of tumour cells but not mesothelial cells. The reduced CSA which was observed after treatment of
fluids with both heparin and thrombin implicated coagulation factors in the manifestation of CSA. It was
concluded that CSA in the fluids was due, at least partly, to fibrin coagulation, and TA was due to unknown
growth factor(s) which may include TGF-p-like activity. The results are discussed in the context of the
aetiology of ovarian carcinoma, and the possible clinical significance of TA.
Following reports that cell-free ascites from cancer patients
could stimulate tumour cell growth in vitro (Uitendaal et al.,
1983) .there has been considerable interest in the growth
promoting properties of these fluids (Broxterman et al., 1987;
Arteaga et al., 1988; Hanauske et al., 1988; Mills et al.,
1988). In an early study we found that a mesothelial cell line
and an ovarian tumour cell line showed different responses to
the same fluid. Whereas tumour cells were stimulated by
fluids from patients with benign and malignant tumours as
well as non-tumour conditions, mesothelial cells were
stimulated more specifically by the tumour-related fluids. It
therefore appeared that the response of mesothelial cells
could be an indicator of the presence of undefined tumour
marker(s). The present study was carried out to investigate
this possibility using a variety of fluids. These included cyst
fluids, ascitic fluids and peritoneal fluids from patients with
cancer of the ovary, benign ovarian tumours and gynaeco-
logical conditions which were not tumour related. The role of
coagulation factors and EGF ± TGF-P in the growth pro-
moting effects observed was also investigated particularly
with respect to EGF, to which mesothelial cells are known to
be sensitive (La Rocca & Rheinwald, 1985).
Materials and methods
Patient groups
Ascitic fluids were collected from ovarian cancer patients
(n = 42), non-ovarian cancer patients (n = 13), non-tumour
patients (n = 4) and one patient with a benign ovarian
tumour. Peritoneal fluids were collected from gynaecology
patients undergoing laporotomy or laporoscopy for non-
tumour related conditions (n = 15), second-look laporotomies
in ovarian cancer patients (n = 5), patients with benign
ovarian tumours (n = 8) and with malignant ovarian tumours
(n = 10). Cyst fluids were collected from borderline tumours
(n = 3), benign tumours (n = 23) and malignant tumours
(n = 11). All fluids were collected without heparin, centri-
fuged at 3,000 r.p.m. for 15 min to remove cells, aliquotted
and frozen at -20°C.
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Target cells
Growth promoting activity of the fluids was assayed against
three target cell populations. These included a mesothelial
cell population, 58MC, from the ascites of a patient with
ovarian cancer and characterised according to criteria des-
cribed elsewhere (Wilson, 1989), the normal rat kidney fibro-
blast cell line, NRK-49F, and one established ovarian
tumour cell line, OAW 42 (Wilson, 1984). OAW 42 was
maintained as a monolayer culture on growth medium con-
sisting of Dulbecco's Modification of Eagle's medium supple-
mented with 10% fetal calf serum, 1 mM glutamine, 1 mM
sodium pyruvate, 20 IU 1' insulin, penicillin and strepto-
mycin (GM). 58MC was also grown as a monolayer on GM
additionally supplemented with 5 ng ml' epidermal growth
factor (EGF) (Gibco) and 0.4 ,Ag ml-' hydrocortisone
(Sigma) (GM + EGF/HC). NRK-49F was maintained as a
monolayer on GM without added pyruvate and insulin. All
lines were subcultured at weekly intervals and stocks were
confirmed to be free of mycoplasma contamination.
Soft agar assay
The growth promoting activity of the fluids was determined
under anchorage-independent conditions. One ml base layers
of 0.5% agar in GM were prepared in 35 mm dishes (Nunc)
and a single cell suspension was overlaid in a I ml layer of
test fluid containing 0.3% agar. 58MC were added at a final
concentration of 105 cells per dish, OAW 42 at 2 x 104 cells
per dish and NRK-49F at 3 x 104 cells per dish. Controls
consisted of the appropriate medium used for routine main-
tenance of the cell type used. The growth promoting activity
of the fluids for tumour cells was designated 'colony stimu-
lating activity' (CSA) and was calculated as:
no. of colonies in test fluid
no. of colonies in controls
Growth promoting activity for the normal cell populations
(58MC and NRK-49K) was designated as 'transforming
activity' (TA) and was expressed as:
no. of colonies in test fluid
no. of colonies in GM + EGF/HC
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Colony formation was expressed as a fraction of colonies
formed in the presence of EGF/HC because this gave a
standard reference point for defining the mitogenic capability
of the normal cell populations, and improved the reproduc-
ibility of inter-assay results for TA. Four replicates were
routinely included for each test condition and colonies were
scored as aggregates of >,20 cells for mesothelial cells, >,30
cells for tumour cells and > 50 cells for NRK-49F cells after
7-10 days incubation at 37°C in an humidified atmosphere
containing 5% CO2. Standard deviations were generally
< 10-15% of the mean values in each test condition,
although higher values did occasionally occur.
Spreading activity
Some fluids induced spreading of mesothelial cells in soft
agar. Spread cells showed a similar appearance to cells grow-
ing in monolayer, exhibiting an elongated shape which was
sufficiently flattened to show the nucleus and nucleolus of the
cell (Figure 1) (Wilson, 1987). Spreading was scored on a
5-point system as follows: - = no spread, + = a few isolat-
ed cells showing spreading, 2 + > 10% <50%, 3 + > 50%
<50%, 4 +> 75%. When fluids did cause spreading, col-
onies were only scored when present as discrete rounded
aggregates; colonies were rarely present when fluids caused
4 + spreading.
Storage time
Some of the data presented were obtained using ascitic fluid
samples which had been stored at - 20°C to -40°C for one
or more years. Several fluids, assayed at different time points
after collection, showed changes in TA. Storage times have
therefore been noted for samples within each group to ensure
that any differences between groups related to sample differ-
ences rather than storage differences.
Reproducibility
TA was determined on two separate occasions within 1
month from the period of collection for nine fluids, using
58MC as target cells. The mean values of TA for each group
of nine was not significantly different (0.53 ± 0.02 vs
0.46 ± 0.16) and the correlation coefficient between paired
Figure 1 Spreading of 58MC in soft agar (4 + ).
results for each fluid showed a significant relationship
(r = 0.673; 2P<0.01. y = 0.504x + 0.189). Repeat samples
obtained from three patients gave similar results (TA = 0.7
and 0.5-5 days between samples; TA = 0.53 and 0.51-14
days between samples; TA = 0.63 and 0.61-1 day between
samples).
Composition offluids
The levels of Na+, K+, Ca2+, P042-, glucose and total
protein were determined for 61 fluids on an American
Monitor Parallel Analyser. Within each fluid category the
different patient groups did not form any distinct subsets
(Table I). Na+, K+ and total protein contents were similar in
the ascitic fluid, cyst fluid and peritoneal fluid groups.
Glucose content was significantly lower in the cyst fluid
group, as was P042- content. LH and FSH levels were
determined in 65 fluids using a RIA kit (Chelsea Hospital for
Women). Results are included only for LH because FSH
levels exceeded the range of the assay. The levels of urogas-
trone (URO-EGF) and TGF-a were determined in 32 unfrac-
tionated fluids using methods which have been described
elsewhere (Gregory et al., 1988, 1989). Briefly, biosynthetic
URO-EGF and TGF-a were derived from synthetic genes
expressed in E. coli and purified to give the human sequence
53 and 50 amino acid residues (Frankling et al., 1986;
Gregory et al., 1988). RIA assays for URO-EGF and TGF-a
were performed using antibodies raised in rabbit and sheep
respectively. The standard curves covered the range 20 pg to
1Ong for URO-EGF and 1Opg to S ng for TGF-a. Cross-
reactivity between URO-EGF and TGF-a was 10 1tg = 40 pg
for both assays. TGF-p-like activity was determined using a
mink lung epithelial cell assay, which shows a dose related
inhibition of tritiated thymidine incorporation in response to
TGF-P like activity (Holley et al., 1983). In the assay system
used 10-1000 pg of TGF-,B gave 3H-Tdr incorporation values
of 80-20% of control values.
Response of target cells to growthfactors
The responses of 58MC, NRK-49F and OAW 42 to EGF +
TGF-P were determined in a soft agar assay in microplates.
Briefly, 100 yd bases of appropriate growth medium (see
Target cells) in 0.5% agar were prepared on a 10 x 6 matrix
in 96-well microplates. Cells were added as a single cell
suspension in a 50 tlI overlay in GM containing 0.3% agar,
at 0.625 x 104 cells for OAW 42, 104 cells for 58MC and
3 x 103 cells for NRK-49F. Growth factors were added in a
50 1tl liquid overlay when the agar was solidified, at 4 x the
final required concentration. Final concentrations used were:
EGF, 0.1, 1, 10 and 25ngmlh'; TGF-P, 1, 10, 100 and
1,000pgml-'; and combinations of each concentration of
EGF with all concentrations of TGF-P. Replicates of three
were used for all test conditions except controls, for which 18
replicates were routinely used. Plates were scored for colonies
as described previously.
Effects ofthrombin and heparin on CSA and TA offluids
Thrombin (Diagnostic Reagents Ltd) at 0.1 and 0.3 U ml'
was added to 14 fluids. After 3 h incubation at 37°C any clots
which had formed were removed and the fluids were then
used in the microplate assay described above, using 58MC
Table I Summary of biochemical profiles
Tot.
Na+ K+ Glucose Ca2+ P042 prot.
Ascites (39)a 130±12 4.1±0.3 4.7± 1.1 1.5±0.4 1.1±0.2 36±16
Cyst fluids (12) 141±7 4.3±0.4 1.5±2.3 2.1±0.4 0.5±0.5 52±19
Peritoneal fluids (10) 139±3 4.4±0.2 5.4±0.6 2.0±0.1 1.1±0.1 45±5
Plasma ranges are: Na+, 133-145nmol1l-; K+, 3.5-5.Onmoll'-; glucose,
3-6 nmol 1-; Ca2, 2.25-2.6 nmol 1- ;P042-, 0.80- 1.45 nmol 1-'; total protein, 59-82
g 1-'. aNo. of fluids in group.104 A.P. WILSON et al.
and OAW 42 as target cells. Fluids were added as a 1501l
liquid overlay to give a final dilution of 50%. Controls
consisted of untreated fluids, GM or GM + EGF/HC with
and without added thrombin at 0.1 and 0.3 U ml-'. Preser-
vative-free heparin (Monoprin) was also added to fluids at
1OU ml-' and to control media at the same concentrations,
and these were included in the same experiments.
Results
Response oftarget cells to growthfactors
The responses of each of the cell lines are shown in Figure
2a,c,e for EGF and TGF-P added separately and in Figure
2b,d,f for combinations of EGF and TGF-P. Briefly, 58MC
and OAW 42 showed an -4-fold and -2-fold increase in
plating efficiency to 25 ng ml-' of EGF, and NRK-49F also
formed colonies (plating efficiency -2.2%) at this concentra-
tion of EGF. Clonogenic growth of 58MC was significantly
enhanced by 1, 10 and 100 pgml-I ofTGF-P, whereas OAW
42 was significantly inhibited, (-50%) and only at 1,000 pg
ml1'. With the combinations, the response of NRK-49F to
EGF was significantly enhanced by TGF-P, as expected
(Anzano et al., 1982), and TGF-P also enhanced the response
of 58MC to 0.1 and 1 ngml-' of EGF, and of OAW 42 to 1
and 25 ngml-' of EGF.
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Transforming activity offluidsfor mesothelial cells
A total of 135 fluids have been tested at 50% dilution for
transforming activity (TA) in a soft agar assay against one
mesothelial cell population (58MC). Results are shown in
Table II for the different patient groups which were investi-
gated.
Mean TA values in the different tumour ascites groups
were significantly higher than the mean TA value for the
control GM group, but the mean TA of the non-tumour
group (liver cirrhosis) was not significantly different from the
control, indicating that higher levels of TA are tumour-
associated. There were no significant differences between TA
values in the different ascites sub-groups. In all the peritoneal
fluid groups, mean TA values were not significantly different
from the control value, although within each sub-group there
was a small percentage of fluids that did have higher TA
values. Most notable was a peritoneal fluid sample (volume
1.5 ml) from a 2LL-patient with residual disease (TA = 1.32).
In the cyst fluid group the difference between benign and
malignant cyst fluids reached borderline significance (storage
times for the two groups were not significantly different, see
Materials and methods), with some benign cyst fluids having
high TA values and some malignant cyst fluids having low
TA values. Two borderline cysts also showed higher TA
values. Because of the difference between benign and malig-
b
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Figure 2 The response of target cell lines to EGF and TGF-P. a,b = 58MC; c,d = OAW 42; e,f= NRK-49F. The horizontal axis
(log scale) for graphs a, c, e shows EGF at 0.1, 1, 10 and 25ngml1' (0) and TGF-P at 1, 10, 100 and 1,000pgml' (0).
PE% = percentage plating efficiency. a,c,e = EGF 0 TGF-P 0. b,d,f = combinations of TGF-P (horizontal axis) and EGF: 0,
25 ng ml 1; E, I0 ngml'; 0, 1 ngml- 1; 0, 0.1 ngml'. The horizontal dashed line on each graph shows the plating efficiency of
target cells in the presence of growth medium (CSA = I; c, d) or in the presence of 2.5 ngml-' of EGF (TA = 1; a,b/e,f).
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nant cyst fluids, the number of fluids showing values ) 0.3
was determined in each group. There was only 1/15 in the
peritoneal fluid control group contrasting with 10/13 in the
untreated ovarian cancer ascites group. The number was also
slightly higher in the malignant cyst fluid group (7/11, 64%)
than in the benign cyst fluid group (11/23, 48%).
Colony stimulating activity (CSA) offluids ofovarian tumour
cells
A total of 58 fluids have been tested at 50% dilution for CSA
in a soft agar assay, using OAW 42 as target cells (Table II).
CSA was generally higher in the different tumour ascites
groups (range 0-24), but the ability to promote tumour cell
growth was not restricted to a clinical tumour condition since
some peritoneal fluids from the gynaecological group also
showed this ability (range 0-21), and the highest values were
present in ascites from patients with liver failure (range
2.9-72). There was, however, significant correlation between
CSA and TA (r = 0.345, n = 44; 2P. 0.05).
Transforming activity offluidsfor NRK-49F cells
A total of 18 fluids were assayed at 50% dilution simultan-
eously against NRK-49F and 58MC for TA. Seven fluids
induced 4 + spreading ofcells in soft agar (see Materials and
methods) and were excluded from the analysis. In the
remaining 11 pairs of results there was no significant correla-
tion (r = 0.135). In 4/6 ascitic fluids and 1/3 malignant cyst
fluids there were large differences between TA values obtain-
ed with the two lines. In 4/5 cases (three ascites and one cyst
fluid) this showed as a high value for NRK-49F (2-5) and a
low value for 58MC (0.014-0.51), and in one case (ascites) a
high value for 58MC (1.41) and a low value for NRK-49F
(0.62).
Correlation between induction ofspreading ofmesothelial cells
in soft agar and CSA offluidsfor OA W42
A number of fluids induced spreading of mesothelial cells in
soft agar (see Materials and methods) and this was more
frequent in certain fluid groups. For final comparison
between fluids results were separated into two categories:
-/+ and 2 + /4+ . The highest incidence of 2 + /4 +
spreading occurred in the control group of peritoneal fluids
(15/21, 71%), ascites from the treated group of ovarian
cancer patients (9/14, 64%) and peritoneal fluids from 2LL
patients (3/7, 42%). The lowest incidence of spreading occur-
red in the cyst fluids (1/31, 3%). Although fluids which
induced spreading of 58MC in soft agar did not induce a
monolayer-like appearance of tumour cells, some flattening
in colony morphology of OAW 42 was observed and it was
further noted that the CSA of fluids which induced 2 + /4 +
spreading of mesothelial cells was significantly higher than
that of fluids which did not (see Table III). The exceptions
were the four fluids from patients with liver failure which
showed high levels of CSA but did not cause spreading of
mesothelial cells.
Effect ofthrombin andheparin on CSA and TA offluids
Because the spread of 58MC in soft agar was believed to be
due to coagulation offibrinogen with subsequent attachment
by mesothelial cells to the fibrin, the effects of preventing fibrin formation by the addition of 0.1 and 0.3 U ml-' of
thrombin or 10 U ml-' of preservative-free heparin were
tested on the CSA and TA of 15 fluids. Results are shown in
Figure 3 for the response of mesothelial cells (a) and tumour
cells (b) to GM, GM + EGF and two representative fluids,
one of which caused spreading of 58MC (162D) and one of
which did not (135D).
Thrombin and heparin had no significant effect on the
colony formation of mesothelial cells in the presence or
absence of 2.5 ng ml-' of EGF, to which the mesothelial cells
showed a 3.8-fold increase in colony formation. Heparin, at
10Uml-', significantly reduced the colony formation of
tumour cells both in the presence and absence of 2.5 ngml-'
of EGF. The tumour cells did not show any response to this
concentration ofEGF, but a 2-fold increase in colony forma-
tion was observed in the presence of EGF and 0.3 U ml-' of
thrombin. With 162D, the addition ofthrombin increased the
colony formation of 58MC and reduced spreading from 4 +
Table III A comparison of CSA for OAW 42 and spreading activity
for 58MC
CSA
Exp. No spread Spreading
No. - +/4 + t 2P
I. 1.5±1.03 (16)a 5.6±7.7 (11) -2.121 <.0.05
2. 2.9±1.90(11) 6.6±1.1 (2) -2.614 .0.02
3. 1.2±0.10 (3) 2.6±1.1 (8) -2.129 .0.05
Results (mean±s.d.) are shown for three separate experiments in
which a number offluids were tested simultaneously against OAW 42
and 58MC. ( ),' no. fluids in group.
Table II Transforming activity (TA) of peritoneal fluids, cyst fluids and effusions for
mesothelial cells and colony stimulating activity (CSA) for ovarian cancer cells
(OAW 42)
Source TA Range >0.3 CSA Range
Peritonealfluids
Gyn. patients 0.15±0.12 (15) 0-0.47 1 (7%) 3.1-1.1 (4) 1.8-4.2
Benign ovarian 0.25±0.28 (8) 0-0.80 3 (37%) 21 (1) 21
Ovarian cancer 0.18±0.20 (10) 0-0.54 2 (20%) 0, 1.1 (2) 0-1.1
2-LL 0.35±0.55 (5) 0.03-1.32 1 (20%) 2.5 (1) 2.5
Cystfluids
Benign ovarian 0.29±0.17 (23)1 0-0.70 11 (48%) 1.4-1.1 (8) 0-3.1
Borderline 0.50±0.50 (3)' 0-0.99 2 (67%) 0, 2 (2) 0-2
Ovarian cancer 0.46±0.38 (11)b 0-0.93 7 (64%) 1.3±0.6 (5) 0.9-2.3
Ascites
Liver cirrhosis 0.18±0.14 (4) 0-0.35 1 (25%) 18.4± 30 (5) 2.9-72
Benign ovarian 0.66 (1) 0.66 1 (100%)
Ovarian cancer, 0.48±0.23 (13)" 0.18-0.98 10 (77%) 3.1 ±4.0 (8) 0-12.5
untreated
Ovarian cancer, 0.44±0.28 (29)C 0-1.22 21 (72%) 3.7±4.7 (17) 0-21
treated
Non-ovarian 0.74± 1.00 (13)' 0-3.80 9 (69%) 4.0±2.0 (9) 0.7-6.4
cancer
( ) no. offluids tested in group for TA or CSA. Significance limits: 2P
.aO.10; bO.025; CO.005; d0.001. Mean TA for GM (colonies in GM/colonies inEGF/HG) was 0.16±0.14
(n= 11).106 A.P. WILSON et al.
a GM EGF 162D 135D determining TA levels in fluids from cystadenomas.
In the malignant group of cyst fluids, TA showed an
_0. increase with increasing stage. Thus the mean TA of stage Ia
,o _ cyst fluids (0.19 ± 0.2, n = 5) was significantly lower (2PS
10 0.001) than that of Ib, Ic or III (0.74 ± 0.20, n = 8). The
,0 r n r borderline group of tumours also showed an interesting
l_l_l_l_L_l_L association between TA and pathology. One fluid with
0 T1T 3 H 0 T1T 3 H 0 T-1T 3 H 0 T 1 T 3 H TA = 0.99 came from a stage lb mucinous tumour of
ob borderline pathology with extension of disease into the Fal-
lopian tube; one with TA = 0.5 came from a patient with a
Do mucinous borderline tumour who had had a benign tumour
removed 12 months previously; and the third with TA =0
nn came from a mucinous borderline tumour, stage la, with no
0 T1T3 H 0 T1T3 H 0 T1T3 H 0 T1T3 H
Figure 3 The effect of thrombin and heparin on the TA (a) and
CSA (b) of GM, GM + EGF and two ascitic fluids (162D,
spreading of 58MC; 135D, no spreading) from ovarian cancer
patients. 0, control; T.I, 0.1 U ml'- thrombin; T-3, 0.IU ml'
thrombin; H, U ml heparin.
to 1 + at 0.3 U ml-' thrombin. Heparin completely abolish-
ed spreading and increased colony formation even more than
0.3 U ml' thrombin. With tumour cells maximum colony
formation occurred in the absence of thrombin and heparin
and the addition of these reduced colony formation, the
lowest value being -10% of the control in 10 U ml-'
heparin. This was parallelled by a change from flattened to
rounded colonies. 135D did not cause spread of 58MC and
the addition of thrombin or heparin had no effect on colony
formation of mesothelial cells. Colony formation by tumour
cells was actually enhanced by 0.1 and 0.3 U ml-' of throm-
bin (cf. EGF + 0.3 U ml-' thrombin) and heparin reduced
colony formation to -60% of the fluid control. Similar
trends to those described with 162D and 135D were also
observed in the group of 15 fluids which included both
benign and malignant fluids. Although enhancement of CSA
by thrombin in this larger group was not a consistent finding,
heparin was always inhibitory.
capsule penetration.
Peritoneal fluid and cyst fluid from the same patient Cyst
fluids and peritoneal fluids were obtained simultaneously
from four patients with benign tumours and seven patients
with maligant tumours. The paired TA results (Figure 4)
showed that TA in peritoneal fluid was higher than that in
cyst fluid in only one patient (149D, benign serous cyst-
adenoma). In two patients the magnitude of TA was masked
by spreading of mesothelial cells (164D, cyst fluid; 188D,
peritoneal fluid) and in the remaining 8 patients it was either
similar (n = 2) or lower (n = 6). The TA values in this group
of cyst fluids reflect the association of TA and stage in
malignant disease, with the two lowest values coming from
cyst fluids of patients with stage Ia tumours (164D and
129D).
TGF-P
Fifty-six fluids have been assayed for TGF-a-like inhibitory
activity using mink lung epithelial cells (MLEC) as targets.
The different values obtained in the MLEC assay are shown
in Figure 5 for the various groups of fluids. 3H-Tdr values
ranged from -30% to -170% indicating the presence of
TGF-p-like activity in some fluids, and also EGF/TGF-z-like
activity. The largest difference was observed between two
groups of five benign and five malignant cysts fluids, but this
difference was not significant (t = 1.599; 2P 0.2). In the
untreated ovarian cancer group there were more samples
showing 3H-Tdr values of > 100% (13/20). 3H-Tdr values
and TA values were compared for 46 fluids giving a correla-
tion coefficient of 0.247 which was of borderline significance
(2P 00.1).
Correlation between age ofpatient, histology, staging and TA
ofcystfluid andperitonealfluid
Age, histology and stage The age of the patient and TA of
the cyst fluid were compared for 24 patients. There was
significant correlation between age of patient and TA in the
pooled benign (14), borderline (3) and malignant (7) groups
(r = 0.529, 2P 0.01). In the benign group only, TA and age
were still significantly correlated (r = 0.742, 2P 0.01) but
the correlation between age and TA was not significant in the
malignant plus borderline group. In the benign group 9/14
tumours were serious or mucinous cystadenomas and six of
these showed TA values ) 0.3. The remaining five tumours
were either ofquestionable origin (3), one was a thecoma and
one was a corpus luteal cyst. None of these showed values
>0.3. Elevated TA, therefore, appeared to be associated
with cystadenomas, and the correlation between age and TA
reflected the decreased incidence of these tumours in the
younger age group. Analysis of LH levels in nine fluids from
the cystadenoma group confirmed the age association, and
LH levels showed a correlation with TA which was of
borderline significance (r = 0.64 2P<0.1) in this group. In
the malignant and benign (cystadenomas) cyst fluids TA
values of 0.74 ± 0.19 and 0.44 ± 0.17 respectively were
obtained. This difference was also of borderline significance
(2P<0.1). When cysts were subdivided into pre- and post-
menopausal cysts, TA values of 0.42 ± 0.16 and 0.77 ± 0.15
were obtained. This difference was more significant (2P<
0.01) implying that menopausal status may be important in
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Figure 4 A comparison of the TA of cyst fluids and peritoneal
fluids from the same patient. 0, cyst fluid; U, peritoneal fluid.
188D peritoneal fluid and 164D cyst fluid induced 4 + spreading
of 58MC. 86D, serous cystadenoma; IOOD, uncertain origin;
149D, serous cystadenoma (recent genital herpes); 188D,
pseudomucinous cystadenoma; 125D, serous carcinomas stage III
(also breast cancer); 144D, pap, cystadenocarcinoma ovary stage
Ic; 156D, mucinous adenocarcinoma stage III; 164D, mucinous
cystadenocarcinoma stage Ia; 170D, serous cystadenocarcinoma
stage Ic; 129D, pseudomucinous cystadenocarcinoma stage Ia;
207D, serous cystadenocarcinoma stage III.
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Figure 5 The effect of fluids on 'H-Tdr incorporation into mink
lung epithelial cells. A, Benign cyst fluids; B, malignant cyst
fluids; C, ascites from untreated ovarian cancer patients; D,
ascites from treated ovarian cancer patients; E, non-ovarian
malignant ascites; F, peritoneal fluids from non-tumour patients.
0, individual results; 0, mean±s.d. for each group.
EGF/TGF-a
Levels of URO-EGF and TGF-a were measured in unfrac-
tionated fluids using RIA. Fluids comprised 16 malignant
ascites, eight benign cyst fluids, three malignant cysts fluids,
one peritoneal washing, one peritoneal fluid from ovarian
cancer and three peritoneal fluids from gynaecological con-
trols. URO-EGF and TGF-x were not detected in 30/32
fluids, but one malignant cyst fluid contained URO-EGF
(1.52 ng ml-', 124D) and one contained TGF-a (0.24 ng
mlh', 129D).
Discussion
The results of this study confirmed our earlier findings that
tumour cells and mesothelial cells showed different responses
to the same fluids. CSA was found in all groups of fluids
tested and was neither cancer-associated nor tumour-
associated since peritoneal fluids from controls and ascites
from cirrhotic patients showed high levels of CSA. TA,
however, at values of >0.3 was more specifically associated
not only with fluids from tumour patients (malignant or
benign) but was also found most frequently in either ascitic
fluids or cyst fluids and rarely in peritoneal fluids, indicating
its derivation from tumour cells rather than a host reaction
to the disease. This association was emphasised by the dis-
covery that TA was usually higher in cyst fluids than perito-
neal fluids from the same patient, a finding which is in
accordance with those of other studies which have looked at
tumour markers in cyst fluids, serum and peritoneal fluid
(Van Nagell et al., 1975; Derricks-Tan et al., 1987; Halila et
al., 1987). In benign and malignant cyst fluids increasing TA
values were significantly correlated with increasing age,
reflecting the association of TA with the serous and
mucinous cystadenomas which have a low incidence in the
younger age group. Increasing TA values in cyst fluid were
also significantly correlated with increasing LH levels in the
cystadenoma/carcinoma group, which suggests a similar rela-
tionship between TA/menopausal status and menopausal
status/ovarian cancer. Although it has generally been
assumed that malignant cystadenocarcinomas arise from
benign cystadenomas there is no direct evidence to support
this view (Fox, 1990; Anderson, 1990). The finding that TA
is frequently elevated in malignant cyst fluids, but that it may
also be elevated in benign cyst fluids implies that this pheno-
menon precedes rather than parallels transformation since
some malignant cysts do not show high levels of TA. Higher
TA values in the most advanced stage tumours might be
taken as an indication that the combination of elevated TA
and transformation is linked with a more aggressive malig-
nancy. This parameter may therefore prove to be useful in
further defining the potential biological behaviour of a
tumour and in understanding the relationship between benign
and malignant cysts with respect to the aetiology of ovarian
cancer. It could be of particular relevance in the analysis of
ovarian cyst aspirates in conjunction with a screening pro-
gramme, and also in treatment decisions for early ovarian
cancer.
The nature of the putative growth factors remains unclear.
Although the magnitude of the response obtained with some
of the fluids were comparable to those obtained with 0.1-10
ngml-l of EGF, neither TGF-c nor EGF was detected by
RIA except in two malignant cyst fluids, which contrasts
with other studies, in which high levels of TGF-a were found
in ascitic fluids (Arteaga et al., 1988; Hanauske et al., 1988).
Reasons for the discrepancy are unclear, although it may
relate to differences between the antibodies used. Evidence
for the presence of TGF-P in some fluids is stronger, and is
indicated both by the results with NRK-49F cells and
MLEC. The concentrations predicted by these bioassays were
generally in the region of 10-I00 pgml-' and these concen-
trations of TGF-P alone enhanced the growth of 58MC. In
the presence of EGF, these concentrations of TGF-P also
enhanced the growth of OAW 42 and of 58MC beyond that
obtained in the presence of either TGF-P alone or EGF
alone. Levels of at least 1,000 pg ml-' of TGF-P appeared
necessary for inhibition of clonogenic growth of OAW 42.
The function of TGF-P is of interest, since Mullerian inhib-
iting substance (MIS), which is structurally related to TGF-P,
has been reported to inhibit ovarian tumour cell growth in a
nude mouse model (Donahoe et al., 1981), although in a
more recent study recombinant MIS was inhibitory against
only a small percentage of the tumours tested (Wallen et al.,
1989).
Mesothelial cells are capable of responding to a wide range
of growth factors in monolayer (Gabrielson et al., 1988;
Laveck et al., 1988) and it is quite likely that the growth
factor content of the fluids is pleomorphic. Whilst TGF-.a
may be implicated, other results exclude not only TGF-o, but
also indicate that the growth factor is specific to ovarian
cancer (Mills et al., 1988). In this study the factors responsi-
ble for CSA and TA are not necessarily identical since
elevated TA is tumour-associated whereas CSA is not and
there is some indication that coagulation factors may be
involved in CSA. Enhanced tumour growth in soft agar may
be due to fibrin/fibrinogen polymerisation thus providing a
matrix for tumour cell growth. Interestingly heparin had no
effect on TA, apart from abolishing spreading, implying
different target cell sensitivities to heparin. In most studies
fluids have been collected with 1OUml-' of heparin and
although Broxterman et al. (1987) reported that heparin had
no effect on their target cells, it would appear that this is
variable, and we would therefore recommend that heparin
should be used with caution when analysing growth promot-
ing activity of fluids. Other information which implicates
coagulation factors as perhaps worthy of further study in
ovarian cancer includes the abnormally high levels of fibrin
degradation products (FDPs) and plasminogen activator in
ascitic fluids (Svanberg & Astedt, 1975); the effects which
have been achieved using anticoagulant therapy with war-
farin in cancer treatment (McCulloch & George, 1989;
Zacharski et al., 1984); the use of fibronolytic agents (tranex-
amic acid) to treat ascites (Astedt et al., 1977; Kikuchi et al.,
1986) and the role of thrombin as a mitogenic hormone
(Bar-Shavit et al., 1986; Medrano et al., 1987).
By using different target cell lines to determine growth
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promoting activity in ascitic fluids, cysts fluids and peritoneal
fluids we have shown, using tumour cells, that there is a
non-specific activity (CSA), and that there is a tumour-
associated activity (TA) which is only apparent using meso-
thelial cells as targets. Further studies on the differences
between benign and malignant cysts fluids, the relationship of
TA with menopausal status in benign cysts and with stage in
malignant cysts may reveal a useful biological marker for
improving our understanding of the aetiology of ovarian
cancer.
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